Stannous Fluoride Toothpaste for Reduction and Treatment of Gingivitis
2026年6月5日 更新者:Church & Dwight Company, Inc.
Efficacy of a Stannous Fluoride Toothpaste in the Reduction and Treatment of Gingivitis: A Randomized Controlled Trial
This study evaluated the efficacy of a stannous fluoride toothpaste compared to a sodium fluoride control toothpaste in reducing gingivitis, bleeding, and plaque over a 12-week period.
A total of 132 subjects were randomized to one of two treatment groups and assessed at baseline and at Weeks 2, 4, 8, and 12 using standardized clinical indices, including the Modified Gingival Index (MGI), Bleeding Index (BI), and Plaque Index (PI).
研究概览
研究类型
介入性
注册 (实际的)
133
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Ontario
-
Mississauga、Ontario、加拿大、L5N 6J2
- All Sum
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
是的
描述
Inclusion Criteria:
- Male or female subjects aged 18 to 65 years (inclusive)
- Provided written informed consent prior to participation
- Able to brush their own teeth on a daily basis
- In good general health based on medical history review
- Minimum of at least 18 natural, scorable teeth
- Mean plaque index score ≥ 1.95
- Mean baseline gingival index score ≥ 1.70 and ≤ 3.0
- Agreed to refrain from use of all oral hygiene products other than those supplied for the study
- Agreed to refrain from oral hygiene, eating, drinking, and chewing gum for approximately 12 hours prior to study visits
- Agreed not to undergo dental prophylaxis or elective dental procedures during the study
- Willing and able to comply with study procedures and visit schedule
Exclusion Criteria:
- Physical limitations or restrictions that preclude normal tooth brushing
- Requirement for premedication prior to dental treatment
- Pregnancy or intent to become pregnant during the study period
- Use of tobacco or nicotine products
- Poor oral hygiene defined as >40 bleeding sites
- Presence of dental caries or calculus deposits that may interfere with plaque assessments
- Major oral hard or soft tissue lesions or trauma at baseline
- Presence of fixed or removable orthodontic appliances
- Dental prophylaxis within 1 month prior to baseline visit
- History of significant adverse events, allergy, or irritation related to oral hygiene products
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Sodium Fluoride Control Dentifrice
Dentifrice containing sodium fluoride, serving as the control comparator
|
Comparator toothpaste
|
|
实验性的:Stannous Fluoride Toothpaste
Dentifrice containing stannous fluoride evaluated for gingivitis effect
|
测试牙膏(0.454% SnF)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate the efficacy of a stannous fluoride toothpaste in gingival inflammation
大体时间:12 weeks
|
Change from baseline in whole-mouth Modified Gingival Index (MGI) score at Week 12 Whole-mouth gingival inflammation will be assessed using the Modified Gingival Index (MGI).
Scores are recorded on scorable gingival areas of all scorable teeth using a 0-4 scale, and the whole-mouth MGI score is calculated as the sum of all site scores divided by the number of scorable sites examined.
The primary analysis compares the change from baseline to Week 12 between treatment groups.
|
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evaluate improvements at weeks 2, 4, 8; assess gingival bleeding at weeks 2, 4, 8, and 12 weeks
大体时间:2, 4, 8, and 12 weeks
|
Secondary outcome measures include change from baseline in whole-mouth bleeding index at Weeks 2, 4, 8, and 12...based on scorable gingival areas using the Saxton 0-2 scale
|
2, 4, 8, and 12 weeks
|
|
Evaluate improvements at weeks 2, 4, 8; assess plaque control at weeks 2, 4, 8, and 12 weeks
大体时间:2, 4, 8, and 12 weeks
|
Secondary outcome measures include change from baseline in plaque at Weeks 2, 4, 8, and 12...calculated from disclosed plaque scores on scorable buccal and lingual tooth surfaces using the Soparkar Modification of the Turesky Modification of the Quigley-Hein Plaque Index; lower scores indicate improvement for all measures.
|
2, 4, 8, and 12 weeks
|
|
Evaluate improvements at weeks 2, 4, 8; in whole mouth Modified Gingival Index (MGI) scores
大体时间:2, 4, and 8 weeks
|
Secondary outcome measures include change from baseline in whole-mouth MGI at Weeks 2, 4, and 8, using the Modified Gingival Index (MGI).
Scores are recorded on scorable gingival areas of all scorable teeth using a 0-4 scale, and the whole-mouth MGI score is calculated as the sum of all site scores divided by the number of scorable sites examined.
|
2, 4, and 8 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Annahita Ghassemi、Church & Dwight, Inc.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2025年3月17日
初级完成 (实际的)
2025年6月13日
研究完成 (实际的)
2025年6月13日
研究注册日期
首次提交
2026年6月2日
首先提交符合 QC 标准的
2026年6月5日
首次发布 (实际的)
2026年6月10日
研究记录更新
最后更新发布 (实际的)
2026年6月10日
上次提交的符合 QC 标准的更新
2026年6月5日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
IPD 计划说明
The sponsor does not plan to share individual participant data.
Summary results will be provided as required, but no de identified datasets will be made publicly available.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.